Search
Top Alliance Biosciences: Clinical Trial Application for JT118 Injection Approved by National Medical Products Administration, Primarily Targeting Monkeypox Virus Prevention
2 week ago /
Read about 0 minute
Author：小编
The National Medical Products Administration has accepted the clinical trial application for JT118 injection, developed by Shanghai Top Alliance Biosciences, a controlling subsidiary of Top Alliance Biosciences. This innovative "two-in-one" recombinant protein vaccine features the tandem fusion of monkeypox virus antigens A35 and M1, specifically designed to prevent monkeypox virus infection. As the first of its kind in China to advance to clinical trial stages, this vaccine marks a significant milestone. However, given the extensive development cycle and multiple regulatory approval stages involved in drug development, the ultimate outcome remains uncertain.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
